Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 3,500 Shares of Stock

Posted by George Bondi on Oct 20th, 2026

Cytokinetics, Incorporated (NASDAQ:CYTK – Get Free Report) EVP Fady Malik sold 3,500 shares of the business’s stock in a transaction on Tuesday, October 20th. The shares were sold at an average price of $64.01, for a total transaction of $224,035.00. Following the sale, the executive vice president directly owned 153,902 shares in the company, valued at $9,851,267.02. This trade represents a 2.22% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Fady Ibraham Malik also recently made the following trade(s):

On Tuesday, October 6th, Fady Malik sold 3,500 shares of Cytokinetics stock. The shares were sold at an average price of $61.38, for a total value of $214,830.00.
On Tuesday, September 22nd, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $68.29, for a total value of $239,015.00.
On Tuesday, September 8th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $75.46, for a total value of $264,110.00.
On Tuesday, August 18th, Fady Malik sold 3,500 shares of Cytokinetics stock. The stock was sold at an average price of $75.82, for a total value of $265,370.00.

Cytokinetics Price Performance

Cytokinetics stock traded up $1.30 during trading hours on Tuesday, hitting $63.95. 1,050,323 shares of the stock traded hands, compared to its average volume of 2,126,460. The firm’s 50 day moving average price is $69.88 and its 200-day moving average price is $73.25. The stock has a market capitalization of $7.96 billion, a price-to-earnings ratio of -8.86 and a beta of 0.41. Cytokinetics, Incorporated has a 1 year low of $54.30 and a 1 year high of $88.31.

Cytokinetics (NASDAQ:CYTK – Get Free Report) last announced its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported ($1.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.13. The firm had revenue of $28.62 million during the quarter, compared to analyst estimates of $17.59 million. During the same period in the prior year, the company posted ($1.12) earnings per share. The firm’s revenue for the quarter was down 57.1% on a year-over-year basis. Research analysts forecast that Cytokinetics, Incorporated will post -5.97 earnings per share for the current fiscal year.

More Cytokinetics News

Here are the key news stories impacting Cytokinetics this week:

Positive Sentiment: Health Canada approved MYQORZO for adults with symptomatic NYHA class II-III obstructive HCM. The once-daily oral therapy is designed to reduce cardiac contractility and left-ventricular outflow-tract obstruction, adding Canada to the drug’s growing list of approved markets. Health Canada MYQORZO approval
Positive Sentiment: Coverage highlighted MYQORZO’s growing prescriptions, international launches and encouraging clinical data as potential drivers of broader market adoption and future revenue growth. MYQORZO growth analysis
Positive Sentiment: HC Wainwright reaffirmed its Buy rating and assigned a $140 price target, signaling substantial perceived upside based on Cytokinetics’ pipeline and commercial prospects. HC Wainwright rating
Neutral Sentiment: BofA Securities maintained a Neutral rating but reduced its price target to $81 from $85, reflecting a more cautious valuation view despite continued recognition of the company’s potential. BofA price target update
Neutral Sentiment: Cytokinetics granted stock options covering 60,465 shares and 40,084 RSUs to 29 new employees. The awards support hiring and retention but may create modest future share dilution. Inducement grants announcement
Negative Sentiment: Wall Street Zen downgraded CYTK to Sell, adding a bearish signal to the analyst mix. Wall Street Zen downgrade

Hedge Funds Weigh In On Cytokinetics

Institutional investors and hedge funds have recently modified their holdings of the stock. V Square Quantitative Management LLC grew its holdings in Cytokinetics by 71.5% during the third quarter. V Square Quantitative Management LLC now owns 458 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 191 shares during the period. Nvwm LLC raised its position in Cytokinetics by 5.2% during the third quarter. Nvwm LLC now owns 9,600 shares of the biopharmaceutical company’s stock valued at $633,000 after acquiring an additional 477 shares in the last quarter. Sanders Morris Harris LLC acquired a new position in Cytokinetics in the third quarter valued at approximately $1,549,000. Mirador Capital Partners LP lifted its holdings in Cytokinetics by 3.2% in the third quarter. Mirador Capital Partners LP now owns 208,896 shares of the biopharmaceutical company’s stock valued at $13,768,000 after acquiring an additional 6,526 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in Cytokinetics by 8.6% in the third quarter. GAMMA Investing LLC now owns 2,700 shares of the biopharmaceutical company’s stock valued at $178,000 after acquiring an additional 213 shares during the period.

Analysts Set New Price Targets

CYTK has been the topic of several research reports. Wall Street Zen downgraded shares of Cytokinetics from a “hold” rating to a “sell” rating in a report on Tuesday. Citizens Jmp lifted their price objective on shares of Cytokinetics from $105.00 to $110.00 and gave the company a “market outperform” rating in a research note on Friday, August 7th. Morgan Stanley raised shares of Cytokinetics from an “overweight” rating to a “buy” rating in a report on Tuesday, September 1st. UBS Group reaffirmed a “buy” rating and issued a $104.00 price objective on shares of Cytokinetics in a report on Wednesday, October 14th. Finally, Needham & Company LLC increased their price objective on shares of Cytokinetics from $102.00 to $112.00 and gave the stock a “buy” rating in a research note on Friday, August 7th. Nineteen investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $105.44.

Check Out Our Latest Report on CYTK

About Cytokinetics

(Get Free Report)

Cytokinetics, Incorporated is a biopharmaceutical company focused on discovering and developing medicines that target muscle function and contractility. The company applies muscle biology and sarcomere science to develop potential treatments for cardiovascular and neuromuscular diseases, including conditions in which impaired muscle performance contributes to disease progression.

Its leading investigational program is aficamten, a selective cardiac myosin inhibitor being developed for hypertrophic cardiomyopathy and other potential cardiovascular indications.